<DOC>
	<DOCNO>NCT02353598</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind , parallel-arm study evaluate safety tolerability least two dose level intravenous ( IV ) crenezumab 24-72 participant mild moderate Alzheimer disease ( AD ) ( mini-mental state examination [ MMSE ] 18 28 point , inclusive ) . An optional open-label extension ( OLE ) offer completion initial double-blind stage .</brief_summary>
	<brief_title>A Study Crenezumab Participants With Mild Moderate Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Body weight great equal ( &gt; /= ) 45 kilogram ( kg ) less equal ( &lt; /= ) 120 kg Ages 5090 year , inclusive Availability person ( `` caregiver '' ) , investigator 's judgment , frequent sufficient contact participant able provide accurate information regard participant 's cognitive functional ability , agree provide information clinic visit , require partner input scale completion , sign necessary consent form Willingness ability complete aspect study ; participant capable completing assessment either alone help caregiver Adequate visual auditory acuity , investigator 's judgment , sufficient perform neuropsychological test Clinical diagnosis probable mild moderate AD base national institute neurological communication disease stroke/Alzheimer 's disease relate disorder association ( NINCDS/ADRDA ) criteria probable major neurocognitive disorder due AD mild moderate severity base diagnostic statistical manual mental disorder , version 5 ( DSM5 ) criteria Screening MMSE score 1828 point , inclusive Screening clinical dementia rating global score ( CDRGS ) 0.5 1.0 Screening geriatric depression ( GDS ) 15 score less ( &lt; ) 6 Positive florbetapir amyloid positron emission tomography ( PET ) scan qualitative read conduct core/central PET laboratory Women must postmenopausal surgically sterile Men female partner childbearing potential agree remain abstinent use adequate method contraception define protocol treatment period least 8 week last dose study drug agreement refrain donate sperm period History presence clinically evident vascular disease potentially affect brain , opinion investigator , potential affect cognitive function History presence stroke within previous 2 year document history transient ischemic attack within previous 12 month History severe , clinically significant central nervous system trauma History presence intracranial tumor clinically relevant opinion investigator Presence infection affect brain function history infection result neurologic sequelae History presence systemic autoimmune disorder potentially cause progressive neurologic disease associate cognitive deficit History presence neurologic disease AD may affect cognition Presence superficial siderosis , four cerebral microhemorrhages , evidence prior cerebral macrohemorrhage Inability tolerate magnetic resonance imaging ( MRI ) procedures contraindication MRI History presence atrial fibrillation except one episode resolve 1 year ago treatment longer indicate investigator 's judgment pose risk future stroke Within previous 2 year , unstable clinically significant cardiovascular disease Uncontrolled hypertension Chronic kidney disease Stage &gt; /= 4 , accord national kidney foundation kidney disease outcomes quality initiative ( NKF KDOQI ) guideline chronic kidney disease Impaired hepatic function Clinically significantly abnormal screen blood urine remain abnormal retest History malignancy within 5 year prior screen , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer ; cancer consider likely cure , actively treated anticancer therapy radiotherapy likely require treatment ensue 5 year well cancer consider low probability recurrence allow Known history severe allergic , anaphylactic , hypersensitivity reaction chimeric , human , humanized antibody fusion protein Severe unstable medical condition , opinion investigator sponsor , could expect progress , recur , change extent could put patient special risk , bias assessment clinical mental status patient significant degree , interfere patient 's ability complete study assessment , would require equivalent institutional hospital care Any previous treatment medication use treat Parkinsonian symptom neurodegenerative disorder within 1 year screen even patient take medicine nonneurodegenerative disorder restless leg disorder Typical antipsychotic neuroleptic medication within 6 month screen except brief treatment nonpsychiatric indication Antihemostasis medication within 2 week screen Sedative , hypnotic , benzodiazepine medication within 3 month screen except intermittent use follow sleep anxiety : alprazolam , lorazepam , oxazepam , temazepam , diazepam , shortacting benzodiazepinelike medication</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>